Boston Scientific Corporation

Boston Scientific Corporation is an American medical device company that designs, manufactures, and markets a broad portfolio of less-invasive technologies used to diagnose and treat cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions, generating $20.1 billion in revenue in fiscal 2025.

This is a story about a premier med-tech compounder that built one of the most compelling growth profiles in large-cap healthcare — and then saw three of its highest-multiple growth engines decelerate in the span of a single quarter, resetting both guidance and the stock. Boston Scientific enters mid-2026 trading at roughly half its 2025 peak, having announced a $14.5 billion acquisition of Penumbra that will reshape its balance sheet, and with management cutting full-year organic growth guidance to 6.5–8% from an implied double-digit trajectory. The market is pricing a company whose best growth may be behind it. The question is whether that is right — or whether the FARAPULSE-to-Penumbra pipeline constitutes something closer to a generational product cycle that will look obvious in retrospect.

The file turns on three questions: whether the WATCHMAN slowdown is cyclical or structural, whether Boston Scientific can maintain electrophysiology leadership as PFA competition intensifies, and whether the Penumbra acquisition — launched at the moment of maximum balance-sheet strength and minimum stock price — proves to be an inspired capital-allocation call or a case of buying the top of a cycle with expensive debt.